Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Alaunos Therapeutics, Inc. reported revenue of $0M, down 50.0% year over year. Operating margin was -84500.0% and net margin -83520.0%, on a free-cash-flow margin of -59340.0% with capital expenditure at 1960.0% of revenue. Every figure is computed directly from TCRT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -84500.0% | -83520.0% |
| FY2024 | $0M | -48120.0% | -46790.0% |
| FY2023 | $0M | -685340.0% | -93580.0% |
| FY2022 | $3M | -1201.4% | -1291.2% |
| FY2021 | $0M | -19484.7% | -19786.7% |
How does TCRT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.